Do not take NEXAVAR if you have a specific type of lung cancer (squamous cell) and receive carboplatin and paclitaxel or if you are allergic to sorafenib or any of the other ingredients in NEXAVAR. Before starting NEXAVAR, tell your doctor if you have: allergies, heart problems (including a problem called “congenital long QT syndrome”) or chest pain, bleeding or bruising problems, high blood pressure, any planned surgical procedures, lung cancer or are being treated for lung cancer, kidney problems in addition to kidney cancer, or liver problems in addition to liver cancer. Tell your doctor if you are pregnant or plan to become pregnant and if you are breast-feeding or plan to breast-feed. It is not known if NEXAVAR passes into your breast milk. You and your doctor should decide if you will take NEXAVAR or breast-feed. You should not do both.
continue reading below »


NEXAVAR in Advanced Kidney Cancer

NEXAVAR was analyzed in the largest study ever conducted in patients with advanced kidney cancer.1

This study of 903 patients showed that the growth and spread of cancer was slowed in people who received NEXAVAR compared with people who did not. NEXAVAR was proven to1,2:

  • Almost doubled the average length of time that cancer had not progressed (5.5 months vs. 2.8 months)

Important Safety Information

The most common side effects with NEXAVAR include: diarrhea (frequent or loose bowel movements); tiredness; infection; hair thinning or patchy hair loss; rash; weight loss; loss of appetite; nausea; stomach (abdominal) pain; low blood calcium levels in people with differentiated thyroid cancer.

Ask your doctor if treatment with NEXAVAR is right for you.

Read more about:

References: 1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312-3318. 2. Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100(20):1454-1463.